Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 40 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer MOST POPULAR COVID-19: “We’re having to rebuild and adapt because of coronavirus” July 15, 2020 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them September 10, 2021 Load more HOT NEWS Feeding the Gut Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ NHS staff shortages: What’s needed to build a sustainable cancer workforce? First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2...
